Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval. 

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.